Evidence map›Paper›PMID 27146676›Full record

ArticleAdvances in therapy2016

Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee.

Jeffrey Rosen, Parag Sancheti, Anke Fierlinger, Faizan Niazi, Herman Johal, Asheesh Bedi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Mitochondrial-targeting MnRegenerative biomaterials · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Intra-Articular Injection ofFrontiers in pharmacology · 2018
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Jeffrey RosenDepartment of Orthopaedics and Rehabilitation, New York Presbyterian Queens, New York, USA. rosenje@nyp.org.
Parag SanchetiSancheti Institute for Orthopaedics and Rehabilitation, Maharashtra, India.
Anke FierlingerFerring Pharmaceuticals Inc., Parsippany, NJ, USA.
Faizan NiaziFerring Pharmaceuticals Inc., Parsippany, NJ, USA.
Herman JohalDivision of Orthopaedics, Department of Surgery, Centre for Evidence-Based Orthopaedics, McMaster University, Hamilton, ON, USA.
Asheesh BediDepartment of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA.
Ferring Pharmaceuticals (United States) · USCornell University · USSancheti Institute For Orthopaedics & Rehabilitation · INUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOsteoarthritis (OA), as one of the leading causes of disability, decreases the quality of life for those suffering from the disease and creates a substantial financial burden. Intra-articular hyaluronic acid (HA) can provide relief from the symptoms of OA and multiple HA products are prescribed. The purpose of this study is to examine the single payer cost-effectiveness of various HA products in the treatment of knee OA.

methodsA single payer economic evaluation was conducted comparing Synvisc(®) (Sanofi, USA), Durolane(®) (Bioventus, USA), Hyalgan(®) (Fidia Pharma Inc., USA), Supartz™ (Bioventus, USA), and Euflexxa(®) (Ferring Pharmaceuticals Inc., USA). Utility scores for HA products were obtained by extracting Western Ontario and McMaster Universities Arthritis Index pain, stiffness and function from randomized controlled trials and converting them to health utilities index mark 3 scores. The cost of a treatment included the cost of the HA injection, cost of a knee injection procedure and cost of a doctor's visit for each required injection. Cost-utility in 2015 USD per quality-adjusted life years (QALY) saved was calculated for each HA product, and incremental cost-effectiveness ratios were calculated to compare the effectiveness of HA products to one another and to conventional care.

resultsWhen compared to conventional care, all investigated HA products were cost-effective, assuming a willingness-to-pay threshold of $50,000/QALY gained. The HA product Euflexxa had the most favorable cost-utility ratio ($5785.52/QALY) when compared to all other HA brands.

conclusionThe present study showed several HA products to be cost-effective in comparison to conventional care, with Euflexxa having the most favorable cost/QALY gained ratio compared to the other HA products.

fundingFerring Pharmaceutics Inc.

Indexed as

Hyaluronic AcidInjections, Intra-ArticularOsteoarthritis, KneeCost-Benefit AnalysisHumansQuality-Adjusted Life YearsTreatment OutcomeUnited StatesUtilization ReviewViscosupplementsHyaluronic AcidViscosupplementsCost-effectivenessEuflexxaHyaluronic acidKneeOsteoarthritis

Identifiers

PMID27146676
PMCPMC4957626
OpenAlexW2346712961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.